Evidence map›Paper›PMID 28899898›Full record

ArticleEndocrine connections2017

Investigating the association of rs2910164 with cancer predisposition in an Irish cohort.

T P McVeigh, R J Mulligan, U M McVeigh, P W Owens, N Miller, M Bell, F Sebag, C Guerin, D S Quill, J B Weidhaas and 2 more

Open access · goldAbstract read
In one paragraph

Article in Endocrine connections, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

T P McVeighDiscipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland terri.mcveigh@gmail.com.
R J MulliganDiscipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland.
U M McVeighDiscipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland.
P W OwensDiscipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland.
N MillerDiscipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland.
M BellDepartment of EndocrinologySchool of Medicine, NUI Galway, Galway, Ireland.
F SebagDepartment of Endocrine Surgery Centre hospitalo-universitaire de La ConceptionAssistance Publique Hôpitaux de Marseille, Marseille, France.
C GuerinDepartment of Endocrine Surgery Centre hospitalo-universitaire de La ConceptionAssistance Publique Hôpitaux de Marseille, Marseille, France.
D S QuillDiscipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland.
J B WeidhaasDavid Geffen School of MedicineUniversity of California, Los Angeles, USA.
M J KerinDiscipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland.
A J LoweryDiscipline of SurgeryLambe Institute for Translational Research, School of Medicine, NUI Galway, Galway, Ireland.
Ollscoil na Gaillimhe – University of Galway · IEAix-Marseille Université · FRHôpital de la Conception · FRUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMicroRNAs (miRNAs) are small noncoding RNA molecules that exert post-transcriptional effects on gene expression by binding with cis-regulatory regions in target messenger RNA (mRNA). Polymorphisms in genes encoding miRNAs or in miRNA-mRNA binding sites confer deleterious epigenetic effects on cancer risk. miR-146a has a role in inflammation and may have a role as a tumour suppressor. The polymorphism rs2910164 in the

methodsThe study group comprised patients with breast cancer (BC), patients with differentiated thyroid cancer (DTC) and unaffected controls. Germline DNA was extracted from blood or from saliva collected using the DNA Genotek Oragene 575 collection kit, using crystallisation precipitation, and genotyped using TaqMan-based PCR. Data were analysed using SPSS, v22.

resultsThe total study group included 1516 participants. This comprised 1386 Irish participants; 724 unaffected individuals (controls), 523 patients with breast cancer (BC), 136 patients with differentiated thyroid cancer (DTC) and three patients with dual primary breast and thyroid cancer. An additional cohort of 130 patients with DTC from the South of France was also genotyped for the variant. The variant was detected with a minor allele frequency (MAF) of 0.19 in controls, 0.22 in BC and 0.27 and 0.26 in DTC cases from Ireland and France, respectively. The variant was not significantly associated with BC (per allele odds ratio = 1.20 (0.98-1.46),

conclusionThe rs2910164 variant in

Indexed as

endocrine cancersthyroid

Identifiers

PMID28899898
PMCPMC5640569
OpenAlexW2755707920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.